Eascra Biotech, Inc.

Eascra Biotech, Inc., a Rhode Island-based for-profit biotechnology firm, develops nanotechnology solutions and space-based manufacturing applications for federal research agencies as a prime contractor (60% of recent awards) and as a subcontractor. The company specializes in Janus Base Nanoparticles (JBNs) for drug delivery, combat medical applications, and in-space pharmaceutical manufacturing, with a footprint split between NASA and defense research agencies.

Eascra's recent prime work centers on space-based manufacturing and therapeutic development. The company holds a $7.96 million definitive, firm fixed-price contract from NASA Johnson Space Center, awarded May 11, 2026, for biotechnology research and development in nanotechnology and space manufacturing applications, with performance in Pawtucket, Rhode Island and completion scheduled for June 30, 2029. The firm also received an NSF SBIR Phase I project grant of $274,990 awarded December 15, 2024, focused on developing regulatory pathways for space-manufactured Janus Base Nanoparticles as an advanced drug delivery system for solid tumors, with completion target November 30, 2025. In the defense research sector, Eascra won a $74,974 Air Force Research Laboratory SBIR Phase I purchase order, awarded August 2, 2024, investigating Janus Base Nanoparticles for combat injury rehabilitation and pain management, with ultimate completion November 4, 2024.

Customer concentration is extreme: NASA Johnson Space Center accounts for all measured awards by potential value (three awards, $8 million combined potential value), with the National Science Foundation and the Air Force Research Laboratory research divisions each contributing one award. The company sits as a subcontractor on University of Connecticut and Center for the Advancement of Science in Space platforms, performing business development, regulatory pathway work, and cost-outcome analysis for in-space Janus Base Nanoparticle manufacturing. Activity is limited and episodic — one award in 2023, three in 2024, one in 2026 — with no visible trajectory across the three-year window. The Service Contract Inventory dataset captures minimal engagement: 1.2 FTEs deployed in FY2024 under a named sub-record, reflecting either minimal SCI-reportable service work or a research-and-development-dominant footprint that falls outside SCI thresholds. Combined obligated dollars ($8.6 million across five awards) slightly exceed potential value, indicating acceleration or scope expansion on the NASA definitive contract or its predecessors.